Telomir Pharmaceuticals (TELO) to Release Earnings on Tuesday

Key Points

• Telomir Pharmaceuticals is set to announce its earnings on Tuesday, August 12th, with analysts predicting a quarterly loss of ($0.08) per share.
• As of recently, TELO shares are down 0.8% to $1.82, with a market cap of $54.01 million and a P/E ratio of -4.32.
• A hedge fund, Bank of America Corp DE, increased its stake in Telomir Pharmaceuticals by 283.9% in the last quarter, acquiring an additional 10,880 shares.

Telomir Pharmaceuticals (NASDAQ:TELO - Get Free Report) will likely be posting its quarterly earnings results before the market opens on Tuesday, August 12th. Analysts expect Telomir Pharmaceuticals to post earnings of ($0.08) per share for the quarter.

Telomir Pharmaceuticals (NASDAQ:TELO - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.03. On average, analysts expect Telomir Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Telomir Pharmaceuticals Price Performance

Telomir Pharmaceuticals stock opened at $1.84 on Thursday. Telomir Pharmaceuticals has a 12 month low of $1.12 and a 12 month high of $8.40. The company has a fifty day moving average price of $1.74 and a two-hundred day moving average price of $2.90. The company has a market cap of $54.76 million, a PE ratio of -4.38 and a beta of -0.67.

Institutional Trading of Telomir Pharmaceuticals

An institutional investor recently raised its position in Telomir Pharmaceuticals stock. Bank of America Corp DE raised its stake in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO - Free Report) by 283.9% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 14,713 shares of the company's stock after buying an additional 10,880 shares during the quarter. Bank of America Corp DE's holdings in Telomir Pharmaceuticals were worth $61,000 as of its most recent SEC filing.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.